Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements

Translational Lung Cancer Research

Volumn 3, Issue 2, 2014, Pages 70-74

  Teixidó, Cristina ^a   Karachaliou, Niki ^a   Peg, Vicente ^a   Gimenez Capitan, Ana ^a   Rosell, Rafael ^a,b  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Anaplastic lymphoma kinase (ALK); Fluorescence in situ hybridization (FISH); Immunohistochemistry (IHC); Non small cell lung cancer (NSCLC); Reverse transcription polymerase chain reaction (RT PCR)

Indexed keywords

CANCER DIAGNOSIS; EML4 ALK FUSION GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE REARRANGEMENT; GENETIC VARIABILITY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR DIAGNOSIS; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 84924048197     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2014.02.02     Document Type: Review

References (33)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
2. Chabner BA. Early accelerated approval for highly targeted cancer drugs. N Engl J Med 2011;364:1087-9.
3. Savic S, Bode B, Diebold J, et al. Detection of ALKpositive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5A4 clone. J Thorac Oncol 2013;8:1004-11.
4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
5. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9.
6. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
7. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-23.
8. Chihara D, Suzuki R. More on crizotinib. N Engl J Med 2011;364:776-7; author reply 778.
9. Sholl LM, Weremowicz S, Gray SW, et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013;8:322-8.
10. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012;461:245-57.
11. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012;77:288-92.
12. Karachaliou N, Rosell R. Optimal detection of ALK rearranged lung adenocarcinomas. J Thorac Oncol 2013;8:255-6.
13. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 2008;3:13-7.
14. Li T, Maus MK, Desai SJ, et al. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. J Thorac Oncol 2014;9:18-25.
15. Tanizaki J, Okamoto I, Takezawa K, et al. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive nonsmall-cell lung cancer cells. Br J Cancer 2012;106:763-7.
16. Heuckmann JM, Balke-Want H, Malchers F, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012;18:4682-90.
17. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53.
18. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010;16:5581-90.
19. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010;9:188.
20. Wallander ML, Geiersbach KB, Tripp SR, et al. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 2012;136:796-803.
21. Tuononen K, Sarhadi VK, Wirtanen A, et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. Biomed Res Int 2013;2013:757490.
22. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121-7.
23. Cancer NSCL. NCCN Clinical Practice Guidelines in Oncology. Available online: www.nccn.com. Accessed on May 25. Version 3.2012.
24. Karachaliou N, Costa C, Gimenez-Capitan A, et al. The concomitant presence of echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) EML4-ALK fusion gene in EGFR-mutant non-small-cell lung cancer (NSCLC) patients treated with erlotinib or chemotherapy in the EURTAC trial. MO26.08 Topic: Pathology, Session: MO26-Anatomical Pathology II. WCLC 2013; Mini oral.
25. Weickhardt AJ, Aisner DL, Franklin WA, et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013;119:1467-77.
26. Lee JA, Bubendorf L, Stahel R, et al. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives. Expert Rev Anticancer Ther 2013;13:625-36.
27. Yi ES, Chung JH, Kulig K, et al. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review. Mol Diagn Ther 2012;16:143-50.
28. Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 2013;8:45-51.
29. Martinez P, Hernández-Losa J, Montero Má, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. PLoS One 2013;8:e52261.
30. Paik JH, Choi CM, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALKrearranged adenocarcinoma. Lung Cancer 2012;76:403-9.
31. Riely GJ, Chaft JE, Ladanyi M, et al. Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Canc Netw 2011;9:1328-30.
32. Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013;13:685-700.
33. EML4-ALK monitoring of crizotinib response in blood platelets and plasma of NSCLC patients. 15th World Conference on Lung Cancer October 27-30, 2013; Sydney, Australia. Poster Session 2: Prognostic and Predictive Biomarkers, P2.06-046.